MedTrace Logo

Plasma MicroRNA for Prediction of Hepatocellular Carcinoma

NCT05449847 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-07-08

No results posted yet for this study

Summary

100 patients with diagnosed HCV were evaluated by clinical and ultrasound examination and were categorized as uncomplicated HCV (n=22) and complicated HCV (n=78). All patients were evaluated for hepatosteatosis and liver fibrosis using the computerized hepatorenal index, the hepatic steatosis index, aspartate aminotransferase (AST)/platelet count index (APRI) and the Fibrosis-4 (FIB-4) scores. Blood samples were obtained for estimation of serum levels of liver function tests and plasma levels of microRNA 21 and 126.

Conditions

  • Hepatitis C

Interventions

BIOLOGICAL

Blood Sampling

Blood sampling under a complete aseptic conditions

Sponsors & Collaborators

  • Benha University

    lead OTHER

Eligibility

Min Age
31 Years
Max Age
67 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-13
Primary Completion
2021-12-07
Completion
2022-03-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05449847 on ClinicalTrials.gov